Exercise cut mortality in cancer patients by almost one-quarter

Clinical takeaway: Recommend a supervised aerobic or aerobic-plus-resistance program to patients in cancer treatment; benefit concentrated above 70% program completion. ACSM specifies moderate aerobic exercise three times weekly plus twice-weekly resistance training for symptom outcomes, not survival.

Whether exercise can be so essential as to consider it "survival therapy" in cancer, has divided oncology for a decade. Overall, cancer returns in 20% to 40% of patients even after curative-intent surgery and chemotherapy. Patients of course ask what they can do to shift those odds. The expectation has long been an improvement in fatigue, function, and quality of life, with some hedging on survival. 

Observational cohorts have long tied post-diagnosis physical activity to lower mortality, but confounding kept the survival question open. Guideline bodies have largely split the difference, recommending exercise for symptom control while declining to endorse it as a cancer-control strategy. Randomized data remained scarce until major trials recently began reporting. A new pooled analysis of randomized trials, the first focused specifically on survival endpoints, now tests whether the association holds. 

Structured exercise was associated with a 23% lower risk of death and a 17% lower risk of recurrence or death from any cause, as compared with usual care or education control. All-cause mortality was 18% lower with exercise and cancer-specific mortality 26% lower. Certainty of evidence was moderate for all four outcomes. No significant effects emerged on progression-free survival or pathologic complete response, both limited by small samples and few events, and both rated low certainty. 

Aerobic exercise alone and aerobic plus resistance training were each associated with improved survival. But resistance-only training showed no association, though that rested on a single trial of 129 participants. In an exploratory analysis of patients who completed at least 70% of their prescribed program, associations strengthened across survival, mortality, and recurrence outcomes with the risk of death falling 28%. 

The researchers observe on the potential mechanisms, "Aerobic exercise drives systemic cardiovascular conditioning, immune cell mobilization, and normalization of tumor perfusion, mechanisms directly relevant to systemic tumor control." 

The analysis pooled 21 randomized controlled trials of structured, supervised exercise delivered during or after primary treatment in 8,449 adults with confirmed cancer, drawn from trials across North America, Europe, Australia, and Asia and followed for a weighted average median of 64 months. Breast cancer accounted for 75% of the cohort, and 88% of participants were women. Comparators were usual care, health education, or pharmacologic therapy alone; certainty of evidence was graded moderate for the survival and mortality outcomes largely due to imprecision. 

"Our meta-analysis provides direct, quantified evidence suggesting that the benefits of structured exercise may extend beyond supportive care to outcomes traditionally associated with therapeutic interventions, while underscoring that observed effects are context dependent and sensitive to trial design, conduct, and feasibility," the researchers concluded. 

Ongoing trials will keep refining how exercise is best used in cancer care. Beyond those, the field needs further adequately powered trials that treat long-term overall and disease-free survival as primary endpoints in additional cancer indications. If exercise is to function as a therapeutic adjunct rather than optional support, programs need to offer supervision and behavioral scaffolding to help keep patients on the exercise program. 

Source: Tzang CC, et al. (2026 Sep 15) Br J Sports Med. Structured exercise interventions and survival outcomes in patients with cancer: systematic review and meta-analysis of randomised controlled trials